Eisai Launches Leqembi, an Alzheimer’s Drug, in China for Early-Stage Disease

Japan’s Eisai expects to administer its Alzheimer’s drug Leqembi to 1,500 people in China, with the goal of completing this task by the end of March 2025. Leqembi was approved for use in early-stage Alzheimer’s by China’s NMPA in January. Eisai is Biogen’s partner on Leqembi and other Alzheimer’s therapies. Both companies have stopped promoting another approved Alzheimer’s drug from their partnership, Adulhelm®, which caused brain bleed and offered only marginal efficacy. China is the third country in the world to approve Leqembi, following the US and Japan. More details....

Share this with colleagues: